Skip to main content

Invested IN Indiana

Fueling the Future of Indiana's Life Sciences

As an important source of venture capital for Indiana’s life sciences entrepreneurial community, we play a crucial role in cultivating a supportive ecosystem that drives globally impactful healthcare innovation through strategic funding and partnerships. 

A Tradition of Investing in Innovation

Indiana boasts a deep-rooted history in life sciences, fueled by over a century of pioneering entrepreneurs. Today, it hosts leading global medical firms, building on foundations laid by visionaries like Colonel Eli Lilly, who established Eli Lilly and Company in Indianapolis nearly 150 years ago, now a top pharmaceutical giant worldwide.

The state's northern region is recognized as the orthopedics capital of the world, thanks to early innovators like Revra DePuy and Justin Zimmer, who founded major orthopedics companies in Warsaw. Similarly, Bloomington's Cook Medical, started over 50 years ago by Bill Cook in his apartment, has grown into the world's largest privately-held medical company.

Start-Ups and Growing Investments

BioCrossroads has established itself as an important source of venture capital for Indiana’s life sciences industry through the formation of early-stage life sciences focused and return-driven investment funds. BioCrossroads has also been strongly supported by Indiana’s corporate and academic life sciences leadership, and has partnered with these stakeholders in several ways, including investment and enterprise-formation activities. BioCrossroads is in a strong position to continue to grow Indiana’s life sciences industry through the identification, advancement, and Investment IN the state’s sciences and technology innovation.

Invested IN Life Sciences

2023 Capital Report

The annual BioCrossroads capital report is a summary of investments made across Indiana's life sciences ecosystem over the past year. 

Fueling Future Innovation

Indiana Seed Funds

With its first fund established in 2005, BioCrossroads has focused on identifying, creating, and developing the next generation of leading Indiana-based life sciences companies. With the advent of Indiana Seed Fund III (2018), BioCrossroads had nearly $24M assets under management for use in early-stage investment in early-stage biotechnology, pharmaceutical, medical device, diagnostics, ag-biotech, and health information technology products and platforms.

Portfolio Companies

30 life sciences companies have received investments from the seed funds managed by BioCrossroads and have gone on to raise more than a half-billion dollars in additional venture investment.

Significant exits include Calibrium and MB2, both acquired by Novo Nordisk in 2015, Assembly Biosciences (Nasdaq:ASMB), and Sexton Biotechnologies, purchased by BioLife Solutions (Nasdaq:BLFS) in 2021.

Here's a look at selected companies that have benefited from Indiana seed fund investments.